热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE anti-mouse CD279 (PD-1) Antibody
产品名称：
PE anti-mouse CD279 (PD-1) Antibody
产品类别：
抗体
产品编号：
135205
产品应用：
135205
[价格]
规格 价格 库存
50µg ￥ 1428 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References

(PubMed link indicates BioLegend citation)
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  6. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  2. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  3. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
  4. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  5. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  6. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  7. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  8. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  9. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  10. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  11. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  12. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  13. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  14. Lu SX, et al. 2021. Cell. . PubMed
  15. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  16. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
  17. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  18. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  19. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  20. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  21. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  22. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
  23. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  24. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  25. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  26. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  27. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  28. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  29. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  30. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
  31. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
  32. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  33. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  34. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
  35. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  36. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  37. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  38. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  39. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  40. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  41. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  42. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  43. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
  44. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
  45. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  46. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  47. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  48. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  49. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  50. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  51. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  52. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  53. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  54. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  55. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  56. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  57. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  58. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  59. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
  60. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_1877232 (BioLegend Cat. No. 135205) AB_1877231 (BioLegend Cat. No. 135206)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线